Lykan combines decades of industry experience with a drive to save lives. Lykan's goal is to provide the first true end-to-end solution in cell and gene manufacturing; ushering in a new era in the industry. Lykan features clinical & commercial CGT manufacturing paired with revolutionary software and a SMART facility design.
The Team at Lykan Bioscience enjoys a long history of success. The team designed, created, and operated a new generation of immunotherapy operating facilities in California and Georgia, maintaining a 99.5 percent manufacturing success rate quarter over quarter. They have been key players in developing and harnessing cost-effective facilities and manufacturing methods for years. The Team developed and implemented advanced quality control methods that led to substantial improvement that literally drove the companies’ success. The Team is comprised of some of the most trusted and accomplished names in Cell and Gene Therapy manufacturing; who are now redefining the very nature of the CGT industry.
Lykan’s ultimate goal is to provide the first true end-to-end platform completely focused on Cell and Gene Therapy manufacturing. To achieve this goal, they have optimized every step of the manufacturing process, creating new efficient manufacturing solutions along the way.
Collaboration enables their partners to focus on the discovery of new products, while Lykan manages every step of the manufacturing process. They have developed the means to optimize capacity and throughput, while delivering on the highest quality standards in the industry.
The Lykan business model sets the tone to create new CGT standards in the market place. As an MSO, their goal is to provide an end-to-end solution that includes first-in-class manufacturing services paired with state-of-the art software and flexible capacity with the first of its kind smart facility design.
Lykan’s sole motivation and passion is to save lives. The team truly believes collaboration between Lykan and their partners, can bridge the barriers between patients and the life saving therapies they should receive.